Direct Compression Granulation Boundaries for Pugan Powder Tablets

In tableting operations, Pugan Powder is incorporated as the active fraction in dry blends or wet-granulated granules with a formulation addition ratio typically spanning 4.0% w/w to 22.0% w/w, adjusted to deliver the required dose per unit rather than to exceed tablet mass limits. Compliance for such tablets must be demonstrated under EU GMP Part II for active substance handling and 21 CFR 211.110 for in-process blend uniformity, with finished-product testing according to Ph. Eur. 2.9.5 uniformity of mass, Ph. Eur. 2.9.3 dissolution, and USP <905> uniformity of dosage units. In direct compression, the API is pre-blended with a coarse carrier such as dibasic calcium phosphate anhydrous for 10 min in a bin blender at 70% fill volume, then passed through a 500 µm screen; the final blend is compressed on a rotary tablet press at 8 kN to 20 kN main compression force, with tablet hardness maintained between 50 N and 90 N to avoid capping at higher punch speeds. During scale-up from pilot to production rotary presses, the main failure mode is lamination when granule moisture exceeds 2.5% or when the fraction of fines below 75 µm exceeds 20% of the blend; a pre-compression force of 1.5 kN to 3.0 kN and turret speed below 50 rpm are applied to extend dwell time. For wet granulation, Pugan Powder is dispersed in a starch paste or povidone solution prior to high-shear mixing; drying in a fluid-bed dryer to a loss-on-drying endpoint of 1.5% to 2.5% is required before compression. Batch-to-batch variance in direct compression is controlled by sampling 10 points from the final blend and rejecting batches with a relative standard deviation above 3.0%. The terminal finished product type is a non-film-coated or film-coated veterinary tablet for oral administration, normally packed in HDPE bottles with desiccants where moisture sensitivity of the API requires an incoming container moisture vapour transmission rate below 0.5 g/m²/day at 23°C and 75% RH.

Injectable formulations based on Pugan Powder require a different sequence of dissolution, depyrogenation, and terminal sterilisation depending on thermal stability of the active fraction. The formulation addition ratio in solution concentrates is generally set between 1.0% w/v and 8.0% w/v, with batch volume adjusted against the delivered dose per millilitre and the final fill volume per vial or ampoule. Industry compliance for parenteral veterinary products falls under EU Regulation 2019/6, current GMP Annex 1 for sterile manufacture, and Ph. Eur. 5.1.1 sterility; each released batch is also assessed for visible and sub-visible particles using Ph. Eur. 2.9.19 particulate contamination and for osmolality using Ph. Eur. 2.2.32, with limits set by the formulation rather than by default pharmacopoeial boundaries. Downstream production begins with dissolution of Pugan Powder in Water for Injection at 25°C to 40°C, followed by pH adjustment to a target range that maintains solubility without exceeding the buffering capacity of the container-closure system; the bulk solution is recirculated through a 0.22 µm sterilising-grade filter and aseptically filled into glass vials under Grade A laminar flow with Grade B surrounding environment. Where the API is thermostable, terminal sterilisation at 121°C for 15 minutes with an F₀ value not less than 8 is applied; otherwise, aseptic filtration alone is used and pre-filtration bioburden is required to remain below 10 CFU/100 mL before filtration. Batch-to-batch variance in pH adjustment is controlled within ±0.2 pH units, because solubility and chemical stability of the active fraction may shift outside this narrow processing window. The terminal finished product type is a sterile injectable solution or injectable suspension after reconstitution, supplied in amber borosilicate glass vials sealed with bromobutyl rubber stoppers and aluminium caps.

What Limits Capsule Fill Uniformity at Low Drug Loads?

Low-dose capsule filling with Pugan Powder is constrained by the need to keep the active fraction uniformly distributed within a larger excipient mass while avoiding segregation during transfer from the hopper to the dosing disc. The formulation addition ratio in hard gelatin capsule blends usually ranges from 6.0% w/w to 30.0% w/w, with the balance composed of lactose monohydrate or microcrystalline cellulose plus 0.5% w/w colloidal silicon dioxide and 1.0% w/w magnesium stearate as the lubricant. Finished capsules must comply with Ph. Eur. 2.9.1 disintegration and USP <711> dissolution for the relevant veterinary species, and the capsule shell itself must meet USP <2091> weight variation or Ph. Eur. 2.9.5 before filling. In production, Pugan Powder is first passed through a 250 µm sieve to break agglomerates, then mixed with a glidant for 5 minutes in a tumble blender at 85% capacity; the lubricated blend is loaded into an automatic capsule filling machine with pin or dosator settings that avoid over-compaction, and fill weight is controlled every 15 minutes using statistical process control limits of ±3.0% around the target. For moisture-sensitive formulations, the filling suite is held below 40% RH and the empty capsule shells are tested for moisture content below 13.0%; segregation risk is further reduced by maintaining the blend hopper at constant level and by using horizontal ribbon blenders if the drug load is below 10.0% w/w. Blends with a Carr index above 25 are rejected before filling because flow variability directly translates into weight variation and dose non-uniformity at low fill weights. The terminal finished product type is a hard gelatin or hydroxypropyl methylcellulose capsule intended for oral administration to companion or production animals, often packed in PVC/aluminium blister strips with a desiccant sachet when the API is hygroscopic.

Unlike direct compression, dry powder sachet formulations for drinking-water medication present a different uniformity challenge because the final dose is dispensed by the operator into a variable volume of water, not by the manufacturing equipment alone. Pugan Powder is compounded into water-dispersible powders at a formulation addition ratio of 2.0% w/w to 25.0% w/w with carriers such as dextrose monohydrate, sodium citrate, and povidone to improve wetting; the resulting powder must pass a 180 µm sieve and achieve a wetting time below 60 seconds when sprinkled onto still water at 25°C. Compliance for this oral powder form is anchored to Ph. Eur. 2.9.12 sieve test, Ph. Eur. 2.9.36 flowability, and USP <1174> powder flow, while manufacturer in-process checks follow 21 CFR 211.110 sampling for blend uniformity. Downstream production uses a ribbon blender with a working volume between 50% and 70% of gross capacity, with the API first triturated with an equal mass of hydrosoluble carrier for 10 minutes before the remaining carrier is added; the blend is then packed into heat-sealed foil or polyester sachets under nitrogen flushing if oxidation-sensitive, with fill weight variation controlled to ±5.0% at 2 g to 500 g sachet sizes. Batch-to-batch variance is evaluated by sampling 10 points from the mixer and calculating the coefficient of variation, which is required to remain below 5.0%. Sachet seal integrity is tested by vacuum dye penetration at -40 kPa for 2 minutes, with rejection of any unit showing dye intrusion beyond the seal line. The terminal finished product type is a water-soluble oral powder intended for reconstitution into drinking water or milk replacer at the farm, packaged in unit-dose or multi-dose sachets.

When Pugan Powder Enters Feed-Mill Premix Dilution Chains

Medicated premix applications use Pugan Powder at a formulation addition ratio in the first dilution step of 0.5% w/w to 5.0% w/w relative to the total premix, followed by downstream dilution into complete feed at ratios from 1:100 to 1:1000 depending on the authorised veterinary inclusion rate and the target species. This scenario is regulated by EU Regulation 2019/4 on medicated feed, 21 CFR 558 for medicated feed applications, and GMP+ or FAMI-QS certification for feed safety; the premix must also meet ISO 22000 hazard-control prerequisites and, where export-oriented, Codex Alimentarius CAC/RCP 54-2004 for feed hygiene. The downstream production sequence in a feed mill uses a stepwise dilution technique: Pugan Powder is first blended with an equal weight of a carrier such as ground corn cob or lactose in a paddle mixer for 5 minutes, then this intermediate blend is further diluted with the remainder of the carrier in a horizontal ribbon mixer with a mixing time of 15 minutes at 80% of the mixer volume. Cross-contamination control requires the line to be flushed with carrier after each batch and the residue in the next batch to be kept below 0.1% w/w; analytical verification uses HPLC after extraction from feed with recovery limits set at 95.0% to 105.0%.

The terminal finished product type is a free-flowing medicated premix for the manufacture of medicated complete feed or top-dress feed, supplied in multi-wall paper bags with an inner polyethylene liner and labelled with withdrawal periods and carry-over warnings according to regional veterinary medicinal law.

Granule Extrusion-Spheronization for Oral Drench and Feed Top-Dress

Granulation of Pugan Powder into free-flowing granules is used when dust containment and dosing accuracy are required for farm-scale oral administration via feed or water. The formulation addition ratio in granulated products is typically 5.0% w/w to 20.0% w/w, with binders such as hydroxypropyl cellulose or pregelatinised starch added at 1.5% w/w to 3.0% w/w, and the granulation liquid volume set between 12.0% and 20.0% of dry mix mass. Compliance is established by Ph. Eur. 2.9.36 powder flow, Ph. Eur. 2.9.12 sieve test, and pharmacopoeial monographs for oral granules; process validation follows VICH GL1 for analytical procedures and VICH GL2 for process validation. Downstream production uses a high-shear granulator at impeller speeds of 300 rpm to 600 rpm and chopper speeds below 2500 rpm for 2 min to 5 min, followed by extrusion through a 0.8 mm to 1.2 mm screen and spheronization at 400 rpm to 800 rpm for 3 min to 6 min; the pellets are dried in a fluid-bed dryer to a loss-on-drying value below 2.0% and screened between 710 µm and 1400 µm. Spheronization yield is monitored by the mass fraction of pellets with an aspect ratio below 1.2 and a target pellet fraction not less than 85% of the dry mass. Where published data for this specific configuration is limited, the above ranges are derived from harmonised veterinary dossier requirements rather than from a single public monograph. The terminal finished product type is a granulate-filled sachet or bulk granulated pack intended for direct oral dosing, feed top-dress, or subsequent reconstitution into water at the point of use.

For oral solutions and liquid drench formulations, Pugan Powder is processed through a dissolution and pH-adjustment route that differs from dry blending because the final product must remain physically stable across the labelled storage period and across a range of ambient farm temperatures. The formulation addition ratio is generally held between 0.1% w/v and 2.0% w/v, with co-solvents such as ethanol or propylene glycol limited to 10.0% v/v to 20.0% v/v only when aqueous solubility is insufficient, and with a citrate or phosphate buffer system set to maintain pH between 4.0 and 7.0. Compliance for veterinary oral solutions falls under EU Regulation 2019/6 and Ph. Eur. 5.1.3 antimicrobial preservation, with dose uniformity tested by Ph. Eur. 2.9.40 for oral solutions and suspensions, and with extractable-leachable testing on the primary pack according to USP <1664> or the equivalent EMA/CVMP guideline. Production begins with Pugan Powder dissolved in purified water at 30°C to 45°C, followed by filtration through a 10 µm then 0.45 µm filter, addition of preservatives and stabilisers, and final mixing in a closed stainless-steel vessel under nitrogen for oxygen-sensitive formulations; the finished solution is filled into high-density polyethylene or glass bottles with child-resistant closures and calibrated dosing cups or syringes. Antimicrobial preservation challenge testing must demonstrate log reduction against Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis according to Ph. Eur. 5.1.3 criteria for oral preparations. The terminal finished product type is an oral solution or drench solution intended for direct administration to individual animals or for proportioner-based dilution into drinking water.